Liver diseases, gastric diseases
Conditions
Interventions
Group A:Hydromorphone 10 mg, with 0.9% normal saline to prepare 100 ml, bolus dose 0.2 mg / time, lock time 10 min
Group B :Hydromorphone 10 mg, with 0.9% normal saline to prepare 100 ml, bolus dose 0.25 mg / time, lock time 10 min
Group C: Hydromorphone 10 mg, with 0.9% normal saline to prepare 100 ml, bolus dose 0.3 mg / time, lock time 10 min
Sponsors
Run Shaw Hospital Affiliated to Medical College of Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. ASA class I - II subjects; 2. Patients undergoing laparoscopic surgery; 3. The cognitive status of patients was good; 4. Patients aged 18-75 years; 5. Patients with no history of drug abuse, chronic pain, mental illness and other complications during pregnancy.
Exclusion criteria
Exclusion criteria: Exclusion criteria: any of the following was "yes" and the subject could not participate in the trial: 1. Patients who are allergic to hydromorphone or its excipients; 2. Patients who have taken or are taking opioids and non steroidal anti-inflammatory drugs 48 hours before surgery; 3. Patients with severe heart, brain, liver and kidney dysfunction, endocrine system diseases and severe infectious diseases; 4. Patients with suspected or confirmed history of alcohol and drug abuse; 5. Patients with serious mental and psychological disorders who can not cooperate with treatment and language disorders; 6. Patients who changed the operation mode during the operation; 7. Patients who cannot cooperate with surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vas resting and activity pain score; | — |
Countries
China
Contacts
Public ContactYan Chunyan
Run Shaw Hospital Affiliated to Medical College of Zhejiang University
Outcome results
None listed